PT1621208E - Vacinação com adn para tratamento de doença auto-imune - Google Patents

Vacinação com adn para tratamento de doença auto-imune Download PDF

Info

Publication number
PT1621208E
PT1621208E PT05015105T PT05015105T PT1621208E PT 1621208 E PT1621208 E PT 1621208E PT 05015105 T PT05015105 T PT 05015105T PT 05015105 T PT05015105 T PT 05015105T PT 1621208 E PT1621208 E PT 1621208E
Authority
PT
Portugal
Prior art keywords
dna
cells
leu
gly
expression cassette
Prior art date
Application number
PT05015105T
Other languages
English (en)
Portuguese (pt)
Inventor
Lawrence Steinman
Hideki Garren
Pedro Jose Ruiz
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of PT1621208E publication Critical patent/PT1621208E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
PT05015105T 1999-03-12 2000-03-10 Vacinação com adn para tratamento de doença auto-imune PT1621208E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26759099A 1999-03-12 1999-03-12

Publications (1)

Publication Number Publication Date
PT1621208E true PT1621208E (pt) 2010-04-07

Family

ID=23019424

Family Applications (1)

Application Number Title Priority Date Filing Date
PT05015105T PT1621208E (pt) 1999-03-12 2000-03-10 Vacinação com adn para tratamento de doença auto-imune

Country Status (9)

Country Link
EP (3) EP2177228A1 (es)
JP (1) JP2003508346A (es)
AT (2) ATE453404T1 (es)
CA (1) CA2363269C (es)
DE (2) DE60043624D1 (es)
DK (2) DK1168923T3 (es)
ES (2) ES2251974T3 (es)
PT (1) PT1621208E (es)
WO (1) WO2000053019A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544669B2 (en) * 2001-11-21 2009-06-09 The Board Of Trustees Of The Leland Stanford Junior University Polynucleotide therapy
AU2007326171B2 (en) 2006-11-30 2012-11-15 Medipost Co., Ltd. Use of a composition contaning human umbilical cord blood-derived mesenchymal stem cell for inducing differentiation and proliferation of neural precursor cells or neural stem cells to neural cells
CN100571786C (zh) * 2007-03-26 2009-12-23 中国农业大学 一种预防和/或治疗自身免疫疾病的疫苗
KR20100054711A (ko) * 2008-11-14 2010-05-25 메디포스트(주) 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물
SE535625C2 (sv) 2010-10-28 2012-10-16 Toleranzia Ab Nya kompositioner och förfaranden för behandling av autoimmuna och allergiska sjukdomar
ES2658154T3 (es) 2011-02-02 2018-03-08 Medipost Co., Ltd. Uso de ICAM-1 para la prevención o el tratamiento de enfermedades neurológicas
GB201112806D0 (en) * 2011-07-26 2011-09-07 Bauer Johann Use of epitopes inducing specific tolerance for the prevention of tissue rejection
WO2013160865A1 (en) 2012-04-26 2013-10-31 Toleranzia Ab Immunotolerizing fusion proteins for treatment of multiple sclerosis
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
US10898590B2 (en) 2015-09-21 2021-01-26 Kolon Life Science, Inc. Method for delivery of biological molecule to nervous tissue
KR20170034701A (ko) * 2015-09-21 2017-03-29 코오롱생명과학 주식회사 통증 치료용 조성물
WO2023086969A2 (en) * 2021-11-12 2023-05-19 Ichor Medical Systems Inc. Treatment methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891435A (en) * 1993-04-16 1999-04-06 Research Corporation Technologies, Inc. Methods and compositions for delaying or preventing the onset of autoimmune disease
US5939400A (en) * 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
US6274136B1 (en) * 1996-05-29 2001-08-14 University Of Southern California Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease
WO1997046253A2 (en) * 1996-06-03 1997-12-11 Powderject Vaccines, Inc. Immunotherapy for autoimmune disease

Also Published As

Publication number Publication date
ES2338890T3 (es) 2010-05-13
EP1621208A1 (en) 2006-02-01
DK1621208T3 (da) 2010-05-10
DE60023673T2 (de) 2006-07-20
ATE453404T1 (de) 2010-01-15
ES2251974T3 (es) 2006-05-16
EP1168923B1 (en) 2005-11-02
EP1168923A4 (en) 2002-06-26
WO2000053019A1 (en) 2000-09-14
EP2177228A1 (en) 2010-04-21
JP2003508346A (ja) 2003-03-04
ATE308244T1 (de) 2005-11-15
EP1168923A1 (en) 2002-01-09
EP1621208B1 (en) 2009-12-30
DE60023673D1 (de) 2005-12-08
CA2363269C (en) 2012-06-12
CA2363269A1 (en) 2000-09-14
DE60043624D1 (de) 2010-02-11
DK1168923T3 (da) 2006-03-20

Similar Documents

Publication Publication Date Title
US7579328B2 (en) DNA vaccination for treatment of multiple sclerosis and insulin-dependent diabetes mellitus
JP4339406B2 (ja) 免疫療法に使用する医薬の製造におけるＳｅｒｒａｔｅまたはＤｅｌｔａの使用
US5939400A (en) DNA vaccination for induction of suppressive T cell response
US9078843B2 (en) Immunogenic fragments of T-cell receptor constant domains and peptides derived therefrom
US20020072493A1 (en) Activated T cells, nervous system-specific antigens and their uses
CA2363269C (en) Dna vaccination for treatment of autoimmune disease
JP3434510B2 (ja) ミエリン塩基性タンパク質のペプチドフラグメントを用いたｔ‐細胞増殖の抑制
CA2203629A1 (en) Compositions and treatment for multiple sclerosis
Ramírez et al. Induction of resistance to active experimental allergic encephalomyelitis by myelin basic protein‐specific Th2 cell lines generated in the presence of glucocorticoids and IL‐4
EP1575526A2 (en) Dna vaccines encoding heat shock proteins
SK44197A3 (en) Peptides modulating the activity of anti-idiotypic t-cells and pharmaceutical compositions containing them, usable in diagnostics and therapy of diabetes mellitus of i.type
CA2362928A1 (en) Vaccine for house dust mite allergen using naked plasmid dna
Zhang et al. Reversal of spontaneous progressive autoimmune encephalomyelitis by myelin basic protein-induced clonal deletion
BG62348B2 (bg) ваксиниране чрез специфични т-клетъчни популациисрещу заболявания в резултат на патогенни отговори
Steinman et al. Suppressive Immunization with DNA
BG63182B2 (bg) Ваксиниране чрез специфични т- клетъчни популациисрещу заболявания в резултат на патогенни отговори
WO2003000718A2 (en) Polypeptides comprising t cell epitopes from alpha-fodrin and the uses thereof in treatment of sjögren's syndrome
Karakikes et al. OPEN POSTERS Accessory molecules
BG63183B2 (bg) Анти-идиотипна ваксина срещу заболявания в резултат от патогенни отговори на специфични т-клетъчни популации